Dehydrozingerone for Health & Longevity - Quick Reference Sheet

Dehydrozingerone for Health & Longevity

Created on 07/18/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A ginger-derived, simplified relative of curcumin. In laboratory and animal work it calms inflammation, neutralizes cell-damaging molecules, and helps muscle take up sugar, with early signals for mood and brain protection. No human trials and no agreed dose exist, so every benefit remains an unproven hypothesis, and it is sold as an unregulated product. (Full Review)

Protocol

Dose
400–600 mg twice daily
Manufacturer-suggested; no validated human dose
Timing
Morning & evening, with food
Split dosing matches short half-life
Form
Isolate or standardized ginger
Neither shown superior; start low, experimental
Time to effect
Metabolic effects
Weeks (animal)
Human onset not established; metabolic effects took weeks in mice

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Children
  • Bleeding disorder
  • Within ~2 weeks of scheduled surgery
  • Significant liver or kidney impairment
Key Interactions
  • Antidepressants & MAO inhibitors (sertraline, fluoxetine, phenelzine)
  • Anticoagulants & antiplatelet drugs (warfarin, apixaban, aspirin, clopidogrel)
  • OTC antiplatelet agents (aspirin, high-dose fish oil)
  • Glucose-lowering supplements (berberine, curcumin, alpha-lipoic acid)
  • Blood-thinning supplements (fish oil, ginkgo, garlic, high-dose vitamin E)
  • Glucose-lowering drugs (metformin, sulfonylureas, insulin)

Risk & Side Effects

  • Low: Unregulated ingredient — quality, purity & dosing uncertainty
  • Speculative: Serotonergic/MAO-A interaction, bleeding/antiplatelet risk, pro-oxidant activity at high concentrations, reproductive & developmental unknowns

Monitoring

Marker Target Why
Fasting glucose 70–85 mg/dL Tracks the blood-sugar effect suggested in animals
HbA1c < 5.4% 3-month average blood sugar
hs-CRP < 1.0 mg/L General marker of systemic inflammation
ALT < 25 U/L (men), < 20 U/L (women) Liver-enzyme safety check
Platelet count 150–400 × 10⁹/L Bleeding-risk safety given antiplatelet signal

Cadence: Baseline before starting; recheck at 8–12 weeks, then every 6–12 months if continued; more frequent glucose checks if on glucose-lowering medication

Qualitative Assessment

  • Mood and sense of well-being
  • Daytime energy levels
  • Digestive comfort and tolerance
  • Any unusual bruising or bleeding